0000950170-23-066394.txt : 20231128
0000950170-23-066394.hdr.sgml : 20231128
20231128160509
ACCESSION NUMBER: 0000950170-23-066394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231124
FILED AS OF DATE: 20231128
DATE AS OF CHANGE: 20231128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ellias Helen K.
CENTRAL INDEX KEY: 0002001600
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 231446374
MAIL ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
BUSINESS PHONE: 605-679-6980
MAIL ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4
1
ownership.xml
4
X0508
4
2023-11-24
0001833214
SAB Biotherapeutics, Inc.
SABS
0002001600
Ellias Helen K.
2100 E 54TH STREET NORTH
SIOUX FALLS
SD
57104
true
false
false
false
false
Common Stock
2023-11-24
4
M
false
2857142
A
2857142
I
See Footnote
Series A-1 Convertible Preferred Stock
0.63
2023-11-24
4
M
false
1800
1000
D
Common Stock or Series A-2 Convertible Preferred Stock
2857142
0
I
See Footnote
Reflects the automatic conversion of shares of Series A-1 Convertible Preferred Stock, par value $0.0001 per share ("Series A-1 Preferred Stock"), held by JDRF T1D Fund, LLC ("JDRF") into shares of common stock, par value $0.0001 per share ("Common Stock") of SAB Biotherapeutics, Inc. (the "Issuer"). The Series A-1 Preferred Stock became automatically convertible on November 24, 2023, the first trading day following the announcement of the approval by the stockholders of the Issuer of (i) an amendment to the Issuer's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock of the Issuer and (ii) the issuance of shares of Common Stock upon conversion of the Issuer's Series A-1 Preferred Stock, Series A-2 Convertible Preferred Stock, par value $0.0001 per share ("Series A-2 Preferred Stock"), and Series A-3 Convertible Preferred Stock, par value $0.0001 per share.
Due to a 1,000 character limit, Footnote 2 is a continuation of Footnote 1: The Series A-1 Preferred Stock is subject to a beneficial ownership blocker provision that prevents the Reporting Person from converting the Series A-1 Preferred Stock into Common Stock to the extent such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion, and to the extent the conversion would cause the Reporting Person's beneficial ownership to exceed such maximum percentage, the Reporting Person will receive shares of Series A-2 Preferred Stock in lieu of Common Stock of the Issuer.
These securities are beneficially owned by JDRF, directly. Helen Katherine Ellias, a Managing Director with JDRF, is a member of the board of directors of the Issuer. JDRF is a non-profit organization and the Reporting Person is an employee of such organization. As such, the Reporting Person disclaims beneficial ownership of any securities held by JDRF.
/s/ Katie Ellias
2023-11-28